Delphine Farlay

Delphine Farlay

Auto-generated profile, based on publicly available information

Delphine Farlay

INSERM, UMR 1033, University of Lyon, University Claude Bernard Lyon 1, F69622, Lyon, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2014 in Autophagy
Verified
Journal Article
Open access
MNMarie Nollet
Marie Nollet
SSSabine Santucci-Darmanin
Sabine Santucci-Darmanin
VBVéronique Breuil
Véronique Breuil
RARasha Al-Sahlanee
Rasha Al-Sahlanee
CCChantal Cros
Chantal Cros
VPValérie Pierrefite-Carle
Valérie Pierrefite-Carle
Bone remodeling is a tightly controlled mechanism in which osteoblasts (OB), the cells responsible for bone formation, osteoclasts (OC), the cells specialized for bone resorption, and osteocytes, the multifunctional mechanosensing cells embedded in the bone matrix, are the main actors. Increased oxidative stress in OB, the cells producing and mineralizing bone matrix, has been associated with osteoporosis development but the role of autophagy in OB has not yet been addressed. This is the goal of the present study. We first show that the autophagic process is induced in OB during mineralization. Then, using knockdown of autophagy-essential genes and OB-specific autophagy-deficient mice, we demonstrate that autophagy deficiency reduces mineralization capacity. Moreover, our data suggest that autophagic vacuoles could be used as vehicles in OB to secrete apatite crystals. In addition, autophagy-deficient OB exhibit increased oxidative stress and secretion of the receptor activator of NFKB1 (TNFSF11/RANKL), f...

1 December 1999 in Bone
Verified
Journal Article
Closed access
CSC.M Serre
C.M Serre
DFD Farlay
D Farlay
PDP.D Delmas
P.D Delmas
CCC Chenu
C Chenu

22 January 2010 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
DFDelphine Farlay
Delphine Farlay
GPGérard Panczer
Gérard Panczer
CRChristian Rey
Christian Rey
PDPierre D. Delmas
Pierre D. Delmas
GBGeorges Boivin
Georges Boivin

1 September 2008 in Bone
Verified
Journal Article
Closed access
GBG. Boivin
G. Boivin
YBY. Bala
Y. Bala
ADA. Doublier
A. Doublier
DFD. Farlay
D. Farlay
LSL.G. Ste-Marie
L.G. Ste-Marie
PDP.D. Delmas
P.D. Delmas

1 April 2010 in Bone
Verified
Journal Article
Closed access
YBYohann Bala
Yohann Bala
DFDelphine Farlay
Delphine Farlay
PDPierre D. Delmas
Pierre D. Delmas
PMPierre J. Meunier
Pierre J. Meunier
GBGeorges Boivin
Georges Boivin

1 September 2005 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
DFDelphine Farlay
Delphine Farlay
GBGeorges Boivin
Georges Boivin
GPGérard Panczer
Gérard Panczer
ALAgnès Lalande
Agnès Lalande
PMPierre Jean Meunier
Pierre Jean Meunier
In monkeys, long-term strontium ranelate administration results in a dose-dependent bone strontium uptake (mainly into newly formed bone) that preserves the degree of mineralization of bone and the bone mineral at the crystal level, showing its safety at bone mineral level. Introduction: Strontium ranelate simultaneously increases bone formation and decreases bone resorption, leading to prevention of bone loss and increase in bone mass and bone strength in normal and ovariectomized rats. This study investigated the interactions of stable strontium (Sr) with bone mineral in monkeys after long-term strontium ranelate treatment and after a period of treatment withdrawal. Materials and Methods: Iliac bone was obtained from untreated monkeys, monkeys at the end of a 52-week strontium ranelate administration (200, 500, 1250 mg/kg/day orally), and in parallel groups 10 weeks after the end of strontium ranelate administration (same three doses; n = 3–7). Sr uptake and distribution in bone mineral were quantified by X-ray microanalysis, changes at the crystal level by X-ray diffraction, and the degree of mineralization of bone (DMB) by quantitative microradiography. Results: After strontium ranelate administration, dose-dependent Sr uptake occurred into cortical and cancellous bone, with higher content (1.6 times) in new than in old bone. This Sr uptake decreased (50%) 10 weeks after treatment withdrawal; the decrease occurred almost exclusively in new bone. At the end of strontium ranelate treatment and after its withdrawal, a preservation of crystal characteristics was observed, suggesting that Sr was only faintly linked to crystals by ionic substitution and of DMB. Conclusions: These results show the absence of a deleterious effect of long-term strontium ranelate treatment on bone mineralization, confirming the histomorphometric observations made in postmenopausal osteoporotic women treated with strontium ranelate.